Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Rectal Neoplasms 11 Colorectal Neoplasms 9 Colonic Neoplasms 4 Pancreatic Neoplasms 2 Pathologic Complete Response 1 Neoplasms 1 Neoplasm Metastasis 1 Liver Metastasis Colon Cancer 1 Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 12 Everolimus 10 Nivolumab 8 Etoposide 8 Temozolomide 6 Carboplatin 6 atezolizumab 5 Irinotecan 5 Ipilimumab 5 Fluorouracil 5 Bevacizumab 5 pembrolizumab 4 lutetium Lu 177 dotatate 4 Capecitabine 4 avelumab 3 Paclitaxel 3 IFL protocol 3 surufatinib 2 sintilimab 2 dostarlimab 2 cabozantinib 2 belinostat 2 azaspirane 2 Topotecan 2 Radiosurgery 2 Positron Emission Tomography Computed Tomography 2 PE regimen 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Magnetic Resonance Imaging 2 Leucovorin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Neuroendocrine × FOLFOXIRI protocol × Clear all

NCT04325425 2025-09-30

FOLFIRINEC

Centre Hospitalier Universitaire Dijon

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡